Total
0
Shares
CannPal (ASX:CPL) - Managing Director, Layton Mills
Managing Director, Layton Mills
Source: PR Newswire
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Pet pharmaceutical company CannPal Animal Therapeutics (CP1) is set to be acquired by fellow ASX-listed medicinal cannabis company, AusCann (AC8)
  • The offer values each CannPal shares at 18.4 cents — a 54 per cent premium to its one-week volume-weighted average price
  • In total, the scheme values CannPal at roughly $17.5 million
  • Each CannPal director plans to vote in favour of the scheme and recommends that all shareholders do the same, claiming its a strategic move
  • The integration of the businesses will lead to more resources, staff and the ability to commercialise human and animal health products
  • CannPal’s shares have been trading flat at 12.5 cents since early morning trade and AusCann last traded steady at 14 cents

CannPal Animal Therapeutics (CP1) is set to be acquired by fellow ASX-lister, AusCann (AC8) through a scheme implementation deed.

AusCann is a medicinal cannabis company that makes standardised, controlled dose products, provides educational support to healthcare professionals and generates accessible clinical evidence.

CannPal shareholders, who will first need to give approval to the transaction, will be offered 1.3 new fully paid ordinary shares in AusCann for every share in CannPal. This values each CannPal share at 18.4 cents per share and CannPal at roughly $17.5 million on a fully diluted basis.

This offer symbolises compelling value to CannPal’s shareholders, as it represents a 47.2 per cent premium to CannPal’s last closing price of 12.5 cents and a 54 per cent premium to its one-week volume-weighted average price of 11.95 cents.

Each director of CannPal plans to vote in favour of the scheme and recommends that all shareholders vote in favour as well.

Importantly, CannPal’s largest and founding shareholder, Merchant Opportunities Fund, which holds 19.88 per cent of CannPal, intends to vote in favour of the scheme.

CannPal believes that combining with AusCann will lead to a stronger leadership team, shared research and knowledge across human and animal health, strong financial position and the ability to generate long-term sustainable growth in the U.S., Australia, Middle East and Africa (MEA), and Germany markets.

“There is a great logic to combining Cannpal Animal Therapeutics with AusCann Group with the new business having enhanced capability to exercise the potential for new and stronger commercial pathways,” CannPal Chairman Geoff Starr said.

Specifically, the integration is expected to bring an expanded product portfolio comprising two products in the market, two that are expected to be launched within 12 months, and a medium-term product pipeline across human and animal health.

It will also result in being a larger ASX-listed company with enhanced liquidity, better placed to attract strategic and institutional investors, pursue growth opportunities and increase shareholder value.

“The complementary nature of developing new health solutions for both human and animal and creating a much larger addressable market makes this combination a gamechanger for both companies,” AusCann Chairman Max Johnston concluded.

CannPal’s shares have been trading flat at 12.5 cents since early morning trade and AusCann last traded steady at an even 14 cents.

CP1 by the numbers
More From The Market Herald
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) recieves funding from Quincy Street

Zelira Therapeutics (ZLD) has raised US$5 million (around A$6.68) from US family office fund, Quincy Street Capital.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) pushes ahead with NASDAQ listing

Advanced Human Imaging (AHI) is pushing ahead with a planned NASDAQ listing, after filing a key form with the US Securities and Exchange
Opthea (ASX:OPT) - CEO and MD, Megan Baldwin

" Opthea (ASX:OPT) opens patient enrolment in Asia-Pacific

Opthea (OPT) has opened patient enrolment for its Phase 3 clinical program for the treatment of wet (neovascular) age-related macular degeneration (AMD) in

" TruScreen (ASX:TRU) highlights efficacy of cancer screening technology

TruScreen (TRU) says the results of a new study demonstrate its cervical cancer screening technology to be an effective alternative to other screening